The Commentary to which this Letter to the Editor responds can be found at: http://dx.doi.org/10.3402/iee.v5.29619. A rebuttal to this Letter to the Editor can be found at: http://dx.doi.org/10.3402/iee.v6.31659
To the Editor
In their commentary article, ‘The imperative to develop a human vaccine for the Hendra virus in Australia’, Zahoor and Mudie (Citation1) argue the case for a human Hendra virus (HeV) vaccine. The statements supporting their arguments are incorrect and have the potential to cause confusion and ultimately undermine confidence in current evidence-based risk management strategies, thereby placing equine and human lives at risk.
The central argument in Zahoor and Mudie (Citation1) is that HeV is ‘rapidly mutating’, with consequent loss of efficacy of the equine HeV vaccine, changing clinical syndromes in humans, and infection in new animal species. There is no scientific basis to their central argument. Zahoor and Mudie (Citation1) offer no citations to support their statements regarding the mutation rate of HeV. Indeed, primary research indicates the HeV genome has minimal variability (less than 1% at both the nucleotide and amino acid levels) in both flying-foxes and horses and is highly stable (the same variant has been detected at disparate locations at the same time, and over periods of at least 12 years) (Citation2, Citation3).
There is no evidence that the equine HeV vaccine is becoming less effective. Continuing equine HeV cases do not reflect loss of vaccine efficacy as stated by Zahoor and Mudie (Citation1), but rather a failure of some horse owners to vaccinate their horses. There have been no HeV cases in vaccinated horses. The efficacy and safety of the recombinant equine vaccine has been clearly demonstrated (Citation4–Citation6), and both government and industry animal health authorities strongly recommend its use as ‘the single most effective way of reducing the risk of Hendra virus infection in horses’ (Citation7).
There is no evidence that the nature of human HeV infection is changing. The seven recognised human cases have shared clinical features but are insufficient in number to determine changes over time (Citation8–Citation13).
There is no evidence that recently reported canine cases indicate that HeV is ‘seeking new co-hosts’. The wide host range of HeV in experimental studies is well established (Citation14, Citation15). The two observed cases of natural HeV infection in dogs most likely resulted from exposure to infected horses, or contaminated material from these horses, and their detection may reflect increased surveillance of canines on infected equine premises (Citation16).
There is no evidence that HeV infections ‘are emerging in locations far beyond bats’ typical migratory boundaries’. Several recent publications demonstrate that the spatial occurrence of equine HeV cases reflects the distribution of black and spectacled flying-foxes (Citation17–Citation19).
In conclusion, we express no objection to the development of a human vaccine against HeV; however, we are emphatic that Zahoor and Mudie (Citation1) are unjustified in using viral evolution, vaccine inefficiency, and changing clinical syndromes as motivations. There are no data to support their case.
Conflict of interest and funding
Dr. Broder reports a grant (CRADA) from Zoetis, Inc., outside the submitted work. In addition, Dr. Broder is a coinventor on U.S. Patent No. 8,865,171 and 9,045,532, with royalties paid by Zoetis, Inc., and Australian Patent No. 2005327194 Patent assignees are the United States of America as represented by the Department of Health and Human Services (Washington DC) and the Henry M. Jackson Foundation (Bethesda, MD).
Dr. Restif reports grants from The Royal Society, during the conduct of the study; he further discloses that he is the sponsor of a Junior Research Fellowship supported by the Axa Research Fund.
Dr. Dhand has communicated with Zoetis for submitting a joint ARC linkage project but this submission did not materialize.
Dr. Secombe is a core executive member of Equine Veterinarians Australia.
Notes
The Commentary to which this Letter to the Editor responds can be found at: http://dx.doi.org/10.3402/iee.v5.29619. A rebuttal to this Letter to the Editor can be found at: http://dx.doi.org/10.3402/iee.v6.31659
References
- Zahoor BA, Mudie LI. The imperative to develop a human vaccine for the Hendra virus in Australia. Infect Ecol Epidemiol. 2015; 5: 29619. doi: http://dx.doi.org/10.3402/iee.v5.29619.
- Smith I, Broos A, De Jong C, Zeddeman A, Smith C, Smith G, etal. Identifying Hendra virus diversity in pteropid bats. PLoS One. 2011; 6: e25275.
- Marsh GA, Todd S, Foord A, Hansson E, Davies K, Wright L, etal. Genome sequence conservation of Hendra virus isolates during spillover to horses, Australia. Emerg Infect Dis. 2010; 16: 1767–9.
- Broder CC, Xu K, Nikolov DB, Zhu Z, Dimitrov DS, Middleton D, etal. A treatment for and vaccine against the deadly Hendra and Nipah viruses. Antiviral Res. 2013; 100: 8–13.
- Middleton D, Pallister J, Klein R, Feng Y-R, Haining J, Arkinstall R, etal. Hendra virus vaccine, a one health approach to protecting horse, human, and environmental health. Emerg Infect Dis. 2014; 20: 372–9.
- Australian Pesticides and Veterinary Medicines Authority. Summary of adverse experience reports made to the APVMA about Hendra virus vaccine. 2015. [Online]. APVMA. Available from: http://apvma.gov.au/node/15786 [cited 18 December 2015].
- Hendra Virus Interagency Working Group (Biosecurity Queensland, Australian Veterinary Association, Queensland Health, Workplace Health & Safety Queensland). Hendra virus infection prevention advice. 2014. Available from: https://www.health.qld.gov.au/ph/documents/cdb/hev-inf-prev-adv.pdf [cited 18 December 2015].
- Selvey LA, Wells RM, McCormack JG, Ansford AJ, Murray K, Rogers RJ, etal. Infection of humans and horses by a newly described morbillivirus. Med J Aust. 1995; 162: 642–5. [PubMed Abstract].
- O'Sullivan JD, Allworth AM, Paterson DL, Snow TM, Boots R, Gleeson LJ, etal. Fatal encephalitis due to novel paramyxovirus transmitted from horses. Lancet. 1997; 349: 93–5.
- Paterson DL, Murray PK, McCormack JG. Zoonotic disease in Australia caused by a novel member of the Paramyxoviridae. Clin Infect Dis. 1998; 27: 112–18. doi: http://doi.org/10.1086/514614 [PubMed Abstract].
- Hanna JN, McBride WJ, Brookes DL, Shield J, Taylor CT, Smith IL, etal. Hendra virus infection in a veterinarian. Med J Aust. 2006; 185: 562–4. [PubMed Abstract].
- Wong KT, Robertson T, Ong BB, Chong JW, Yaiw KC, Wang LF, etal. Human Hendra virus infection causes acute and relapsing encephalitis. Neuropathol Appl Neurobiol. 2009; 35: 296–305.
- Playford EG, McCall B, Smith G, Slinko V, Allen G, Smith I, etal. Human Hendra virus encephalitis associated with equine outbreak, Australia, 2008. Emerg Infect Dis. 2010; 16: 219–23.
- Westbury HA, Hooper PT, Selleck PW, Murray PK. Equine morbillivirus pneumonia – Susceptibility of laboratory animals to the virus. Aust Vet J. 1995; 72: 278–9.
- Geisbert TW, Feldmann H, Broder CC. Animal challenge models of henipavirus infection and pathogenesis. Curr Top Microbiol Immunol. 2012; 359: 153–77. [PubMed Abstract].
- Kirkland PD, Gabor M, Poe I, Neale K, Chaffey K, Finlaison DS, etal. Hendra virus infection in dog, Australia, 2013. Emerg Infect Dis. 2015; 21: 2182–5.
- Smith CS, Skelly C, Kung N, Roberts BJ, Field HE. Flying-fox species diversity – A spatial risk factor for Hendra virus infection in horses in Eastern Australia. PLoS One. 2014; 9: 1–7.
- Edson D, Field H, McMichael L, Vidgen M, Goldspink L, Broos A, etal. Routes of Hendra virus excretion in naturally-infected flying-foxes: implications for viral transmission and spillover risk. PLoS One. 2015; 10: e0140670. doi: http://dx.doi.org/10.1371/journal.pone.0140670 [PubMed Abstract] [PubMed CentralFull Text].
- Field H, Jordan D, Edson D, Morris S, Melville D, Parry-Jones K, etal. Spatio-temporal aspects of Hendra virus infection in pteropid bats (flying-foxes) in eastern Australia. PLoS One. 2015; 10: e0144055. doi: http://dx.doi.org/10.1371/journal.pone.0144055 [PubMed Abstract] [PubMed CentralFull Text].